The National Heart, Lung, and Blood Institute (NHLBI) awarded the Project Grant titled "MICROSCOPIC EB-OCT IMAGING TO PREDICT PROGRESSION IN INTERSTITIAL LUNG ABNORMALITIES" under the CFDA 93.837 Cardiovascular Diseases Research program. This $837,883 grant, awarded on June 1, 2024 with a completion date of May 31, 2029, aims to develop an endobronchial optical coherence tomography (EB-OCT) imaging technique to detect microscopic features in interstitial lung abnormalities (ILA) that can predict progression to progressive pulmonary fibrosis (PPF). The primary awardee, The General Hospital Corporation (doing business as Massachusetts General Hospital), will collaborate with a sub-awardee, Brigham & Women's Hospital, to conduct this research across two independent ILA patient cohorts. The goal is to establish an integrative predictive model combining EB-OCT, CT imaging, and plasma biomarkers to identify high-risk ILA patients who would benefit from early interventions to prevent PPF development.
Generated 3/25/25, 4:37 AM